Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats

Vaccine

Volumn 31, Issue 17, 2013, Pages 2169-2176

  Kamphuis, Tobias ^a   Shafique, Muhammad ^a   Meijerhof, Tjarko ^a   Stegmann, Toon ^a,b   Wilschut, Jan ^a   De Haan, Aalzen ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Mymetics BV   (Netherlands)

Author keywords

Adjuvant; Intranasal; RSV; TLR, MPLA; Vaccine

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PHOSPHORYL LIPID A; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; VIROSOMAL RESPIRATORY SYNCYTIAL VIRUS VACCINE; VIROSOME;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPATHOLOGY; LUNG DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; VIRUS SHEDDING; VIRUS TITRATION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; CROSS-PRIMING; CYTOKINES; FEMALE; IMMUNOGLOBULIN A, SECRETORY; IMMUNOGLOBULIN G; LIPID A; LUNG; MICE; MICE, INBRED BALB C; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; SIGMODONTINAE; TH1 CELLS; TOLL-LIKE RECEPTOR 4; VACCINATION; VIROSOMES;

EID: 84875855843     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.02.043     Document Type: Article

References (39)

1. Tregoning J.S., Schwarze J. Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin Microbiol Rev 2010, 23:74-98.
2. Falsey A.R., Hennessey P.A., Formica M.A., Cox C., Walsh E.E. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005, 352:1749-1759.
3. Raboni S.M., Nogueira M.B., Tsuchiya L.R.V., Takahashi G.A., Pereira L.A., Pasquini R., Siqueira M.M. Respiratory tract viral infections in bone marrow transplant patients. Transplantation 2003, 76:142-146.
4. Hall C.B., Long C.E., Schnabel K.C. Respiratory syncytial virus infections in previously healthy working adults. Clin Infect Dis 2001, 33:792-796.
5. Falsey A.R. Respiratory syncytial virus infection in adults. Semin Respir Crit Care Med 2007, 28:171-181.
6. Murphy B.R., Sotnikov A.V., Lawrence L.A., Banks S.M., Prince G.A. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 1990, 8:497-502.
7. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., Parrott R.H. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969, 89:422-434.
8. Chin J., Magoffin R.L., Shearer L.A., Schieble J.H., Lennette E.H. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 1969, 89:449-463.
9. Fulginiti V.A., Eller J.J., Sieber O.F., Joyner J.W., Minamitani M., Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 1969, 89:435-448.
10. Prince G.A., Curtis S.J., Yim K.C., Porter D.D. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol 2001, 82:2881-2888.
11. Murphy B.R., Prince G.A., Walsh E.E., Kim H.W., Parrott R.H., Hemming V.G., Rodriguez W.J., Chanock R.M. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol 1986, 24:197-202.
12. Murphy B.R., Walsh E.E. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol 1988, 26:1595-1597.
13. Delgado M.F., Coviello S., Monsalvo A.C., Melendi G.A., Hernandez J.Z., Batalle J.P., Diaz L., Trento A., Chang H-Y., Mitzner W., Ravetch J., Melero J.A., Irusta P.M., Polack F.P. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 2009, 15:34-41.
14. Waris M.E., Tsou C., Erdman D.D., Zaki S.R., Anderson L.J. Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol 1996, 70:2852-2860.
15. Boukhvalova M.S., Prince G.A., Soroush L., Harrigan D.C., Vogel S.N., The Blanco J.C.G. TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease. Vaccine 2006, 24:5027-5035.
16. Giudice E.L., Campbell J.D. Needle-free vaccine delivery. Adv Drug Deliv Rev 2006, 58:68-89.
17. Hussell T., Humphreys I.R. Nasal vaccination induces protective immunity without immunopathology. Clin Exp Immunol 2002, 130:359-362.
18. Shafique M., Wilschut J., de Haan A. Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands. Vaccine 2012, 30:597-606.
19. Garçon N., Segal L., Tavares F., van Mechelen M. The safety evaluation of adjuvants during vaccine development: the AS04 experience. Vaccine 2011, 29:4453-4459.
20. Garçon N., Wettendorff M., van Mechelen M. Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile. Expert Opin Biol Ther 2011, 11:667-677.
21. Kamphuis T., Meijerhof T., Stegmann T., Lederhofer J., Wilschut J., de Haan A. Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid a in mice. PLoS ONE 2012, 7:e36812.
22. Childers N., Miller K., Tong G., Llarena J., Greenway T., Ulrich J., Michalek S. Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen. Infect Immun 2000, 68:5509-5516.
23. Baldridge J.R., Yorgensen Y., Ward J.R., Ulrich J.T. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine 2000, 18:2416-2425.
24. Stegmann T., Kamphuis T., Meijerhof T., Goud E., de Haan A., Wilschut J. Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation. Vaccine 2010, 28:5543-5550.
25. Pizza M., Giuliani M.M., Fontana M.R., Monaci E., Douce G., Dougan G., Mills K.H.G., Rappuoli R., Del Giudice G. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 2001, 19:2534-2541.
26. Duthie M.S., Windish H.P., Fox C.B., Reed S.G. Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 2011, 239:178-196.
27. Didierlaurent A.M., Morel S., Lockman L., Giannini S.L., Bisteau M., Carlsen H., Kielland A., Vosters O., Vanderheyde N., Schiavetti F., Larocque D., van Mechelen M., Garçon N.A.S04 an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009, 183:6186-6197.
28. Sasaki S., Hamajima K., Fukushima J., Ihata A., Ishii N., Gorai I., Hirahara F., Mohri H., Okuda K. Comparison of intranasal and intramuscular immunization against human immunodeficiency virus type 1 with a DNA-monophosphoryl lipid A adjuvant vaccine. Infect Immun 1998, 66:823-826.
29. Mata-Haro V., Cekic C., Martin M., Chilton P.M., Casella C.R., Mitchell T.C. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007, 316:1628-1632.
30. Heer A.K., Shamshiev A., Donda A., Uematsu S., Akira S., Kopf M., Marsland B.J. TLR signaling fine-tunes anti-influenza B cell responses without regulating effector T cell responses. J Immunol 2007, 178:2182-2191.
31. Parker D., Prince A. Innate immunity in the respiratory epithelium. Am J Respir Cell Mol Biol 2011, 45:189-201.
32. Jia H.P., Kline J.N., Penisten A., Apicella M.A., Gioannini T.L., Weiss J., McCray P.B. Endotoxin responsiveness of human airway epithelia is limited by low expression of MD-2. Am J Physiol Lung Cell Mol Physiol 2004, 287:L428-L437.
33. Ainai A., Ichinohe T., Tamura S-I., Kurata T., Sata T., Tashiro M., Hasegawa H. Zymosan enhances the mucosal adjuvant activity of poly(I:C) in a nasal influenza vaccine. J Med Virol 2010, 82:476-484.
34. Cataldi A., Yevsa T., Vilte D.A., Schulze K., Castro-Parodi M., Larzábal M., Ibarra C., Mercado E.C., Guzman C.A. Efficient immune responses against Intimin and EspB of enterohaemorragic Escherichia coli after intranasal vaccination using the TLR2/6 agonist MALP-2 as adjuvant. Vaccine 2008, 26:5662-5667.
35. Boukhvalova M.S., Prince G.A., Blanco J.C.G. The cotton rat model of respiratory viral infections. Biologicals 2009, 37:152-159.
36. Johansen F-E., Kaetzel C.S. Regulation of the polymeric immunoglobulin receptor and IgA transport: new advances in environmental factors that stimulate pIgR expression and its role in mucosal immunity. Mucosal Immunol 2011, 4:598-602.
37. Bruno M.E.C., Frantz A.L., Rogier E.W., Johansen F-E., Kaetzel C.S. Regulation of the polymeric immunoglobulin receptor by the classical and alternative NF-(B pathways in intestinal epithelial cells. Mucosal Immunol 2011, 4:468-478.
38. Renegar K., Small P., Boykins L., Wright P. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 2004, 173:1978-1986.
39. Renegar K.B., Immunoglobulin Small P.A. A mediation of murine nasal anti-influenza virus immunity. J Virol 1991, 65:2146-2148.